Literature DB >> 12885754

Prophylactic efficacy of topical temporin A and RNAIII-inhibiting peptide in a subcutaneous rat Pouch model of graft infection attributable to staphylococci with intermediate resistance to glycopeptides.

Oscar Cirioni1, Andrea Giacometti, Roberto Ghiselli, Giorgio Dell'Acqua, Yael Gov, Wojciech Kamysz, Jerzy Lukasiak, Federico Mocchegiani, Fiorenza Orlando, Giuseppina D'Amato, Naomi Balaban, Vittorio Saba, Giorgio Scalise.   

Abstract

BACKGROUND: Bacteria that adhere to implanted medical devices play an important role in industry and in modern medicine. Staphylococci are among the most common pathogens that cause biomaterial infections. Vascular prosthetic graft infection is one of the most feared complications that the vascular surgeon treats, frequently resulting in prolonged hospitalization, organ failure, amputation, and death. A rat model was used to investigate the topical efficacies of temporin A and the quorum-sensing inhibitor RNAIII-inhibiting protein (RIP) as prophylactic agents of vascular prosthetic graft infections caused by Staphylococcus aureus and Staphylococcus epidermidis with intermediate resistance to glycopeptides. METHODS AND
RESULTS: Graft infections were established in the back subcutaneous tissue of adult male Wistar rats by implantation of Dacron prostheses 1 cm2 followed by topical inoculation with 2x10(7) colony-forming units of bacterial strains. The study included, for each staphylococcal strain, a control group (no graft contamination), a contaminated group that did not receive antibiotic prophylaxis, and 6 contaminated groups that received grafts soaked with temporin A, RIP, rifampin, temporin A plus RIP, RIP plus rifampin, or temporin A plus RIP. The infection was evaluated by quantitative agar culture. When tested alone, temporin A and RIP showed comparable efficacies, and their efficacies were significantly higher than that of rifampin against both strains. All combinations showed efficacies significantly higher than that of each single compound. The combinations of temporin A and RIP exerted the strongest antistaphylococcal efficacies, eliminating infection by 100%.
CONCLUSIONS: The results of the present study make these molecules potentially useful for antimicrobial chemoprophylaxis in vascular surgery.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12885754     DOI: 10.1161/01.CIR.0000083717.85060.16

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  16 in total

1.  Adjunctive therapies in the treatment of osteomyelitis.

Authors:  Robert C Fang; Robert D Galiano
Journal:  Semin Plast Surg       Date:  2009-05       Impact factor: 2.314

Review 2.  Role of quorum sensing in bacterial infections.

Authors:  Israel Castillo-Juárez; Toshinari Maeda; Edna Ayerim Mandujano-Tinoco; María Tomás; Berenice Pérez-Eretza; Silvia Julieta García-Contreras; Thomas K Wood; Rodolfo García-Contreras
Journal:  World J Clin Cases       Date:  2015-07-16       Impact factor: 1.337

3.  Transcriptional profiling of target of RNAIII-activating protein, a master regulator of staphylococcal virulence.

Authors:  Moshe Korem; Yael Gov; Madanahally D Kiran; Naomi Balaban
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

4.  Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP.

Authors:  Naomi Balaban; Oscar Cirioni; Andrea Giacometti; Roberto Ghiselli; Joel B Braunstein; Carmela Silvestri; Federico Mocchegiani; Vittorio Saba; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

5.  Treatment and prevention of Staphylococcus epidermidis experimental biomaterial-associated infection by bactericidal peptide 2.

Authors:  Paulus H S Kwakman; Anje A te Velde; Christina M J E Vandenbroucke-Grauls; Sander J H van Deventer; Sebastian A J Zaat
Journal:  Antimicrob Agents Chemother       Date:  2006-09-25       Impact factor: 5.191

6.  RNAIII-inhibiting peptide affects biofilm formation in a rat model of staphylococcal ureteral stent infection.

Authors:  Oscar Cirioni; Roberto Ghiselli; Daniele Minardi; Fiorenza Orlando; Federico Mocchegiani; Carmela Silvestri; Giovanni Muzzonigro; Vittorio Saba; Giorgio Scalise; Naomi Balaban; Andrea Giacometti
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

7.  Temporin A soaking in combination with intraperitoneal linezolid prevents vascular graft infection in a subcutaneous rat pouch model of infection with Staphylococcus epidermidis with intermediate resistance to glycopeptides.

Authors:  Andrea Giacometti; Oscar Cirioni; Roberto Ghiselli; Fiorenza Orlando; Giuseppina D'Amato; Wojciech Kamysz; Federico Mocchegiani; Valerio Sisti; Carmela Silvestri; Jerzy Łukasiak; Marco Rocchi; Vittorio Saba; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

8.  RNAIII-inhibiting peptide enhances healing of wounds infected with methicillin-resistant Staphylococcus aureus.

Authors:  Oriana Simonetti; Oscar Cirioni; Roberto Ghiselli; Gaia Goteri; Alessandro Scalise; Fiorenza Orlando; Carmela Silvestri; Alessandra Riva; Vittorio Saba; Kiran D Madanahally; Annamaria Offidani; Naomi Balaban; Giorgio Scalise; Andrea Giacometti
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

9.  A chimeric peptide composed of a dermaseptin derivative and an RNA III-inhibiting peptide prevents graft-associated infections by antibiotic-resistant staphylococci.

Authors:  Naomi Balaban; Yael Gov; Andrea Giacometti; Oscar Cirioni; Roberto Ghiselli; Federico Mocchegiani; Fiorenza Orlando; Giuseppina D'Amato; Vittorio Saba; Giorgio Scalise; Sabina Bernes; Amram Mor
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

10.  Inactivation of traP has no effect on the agr quorum-sensing system or virulence of Staphylococcus aureus.

Authors:  Lindsey N Shaw; Ing-Marie Jonsson; Vineet K Singh; Andrej Tarkowski; George C Stewart
Journal:  Infect Immun       Date:  2007-06-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.